This card has a few issues.

Firstly, the treatment regimen is largely the same whether or not the patient is pre/postmenopausal, although EOC typically presents in postmenopausal women (1,2).

Secondly, the chemotherapy regimen is low yield, but outdated (1).

Thirdly, much of the extra is somewhat irrelevant to the card. Fertility preservation is only used in management of select malignant ovarian neoplasms (2,3) and TAH and BSO is standard of care in both pre and postmenopausal women (except in the case of early-stage EOS, for which fertility preservation can be considered) because EOC typically presents at an advanced stage and TAH and BSO is part of staging and surgical treatment (2).

If these changes are unable to be made, I would recommend that this content be integrated to the deck elsewhere or that new cards be generated to cover this content gap in treatment of ovarian neoplasms.

Sources
1. https://next.amboss.com/us/article/aO0QIT?q=epithelial%20ovarian%20cancer%20treatment#Yf12090dc1faa443872104a241e3ecb99

2. https://www.uptodate.com/contents/overview-of-epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum?search=epithelial%20ovarian%20cancer%20treatment&source=search_result&selectedTitle=4%7E150&usage_type=default&display_rank=4#H6099451


3. Fertility preservation option in young women with ovarian cancer
National Institutes of Health (NIH) (.gov)
https://pmc.ncbi.nlm.nih.gov › articles › PMC5549777